A few studies of small molecule Gal3 inhibitors have been registered for clinical trials, mostly for lung and liver fibrosis (www.clinicaltrials.gov (accessed on 20 February 2023)) (see Table 1 for the details). Here, LGALS3 is linked to Hepatic fibrosis.